Successful treatment of Acute Fulminant Liver Failure due to Hepatitis B virus with Entecavir in patients with contra-indications to liver transplant

Authors

  • Mukul Bhattarai Geisinger Health System, Danville, PA
  • Pardeep Bansal Geisinger Health System, Danville, PA
  • Michael Komar Geisinger Health System, Danville, PA
  • Robert E Smith Geisinger Health System, Danville, PA
  • Hitekshya Nepal Geisinger Health System, Danville, PA

DOI:

https://doi.org/10.3126/jaim.v2i2.8780

Keywords:

Entecavir, Liver transplant, Fulminant Hepatic Failure, Hepatitis B Virus

Abstract

There are no randomized clinical trials on efficacy of Entecavir in Fulminant Hepatic Failure (FHF) due to Hepatitis B Virus (HBV). Definitive treatment of FHF remains Liver Transplant. However, availability of cadaveric donor organs is limited, and many of the patients with FHF may not be candidates for Liver Transplantation. There are only few case reports on beneficial effects of Entecavir in FHF due to HBV. We present 2 cases of FHF due to HBV. Both patients had severe liver cell damage among which one was immunocompromised. Transaminases were elevated up to 200 times the normal. Both were not transplant candidates, and were successfully treated with Entecavir resulting in significant clinical and transaminases improvement within 7 days of starting Entecavir.

DOI: http://dx.doi.org/10.3126/jaim.v2i2.8780

 Journal of Advances in Internal Medicine 2013;02(02):67-70

Downloads

Download data is not yet available.
Abstract
914
PDF
616

Downloads

Published

2013-09-29

How to Cite

Bhattarai, M., Bansal, P., Komar, M., Smith, R. E., & Nepal, H. (2013). Successful treatment of Acute Fulminant Liver Failure due to Hepatitis B virus with Entecavir in patients with contra-indications to liver transplant. Journal of Advances in Internal Medicine, 2(2), 67–70. https://doi.org/10.3126/jaim.v2i2.8780

Issue

Vol. 2 No. 2 (2013)

Section

Case Reports

License

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator.